Los Angeles Capital Management LLC Acquires 3,742 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Los Angeles Capital Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 204,024 shares of the biopharmaceutical company’s stock after acquiring an additional 3,742 shares during the period. Los Angeles Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $4,258,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Larson Financial Group LLC boosted its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $65,000. KBC Group NV lifted its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $134,000. Finally, Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at about $151,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CPRX shares. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. HC Wainwright boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Stephens reissued an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Trading Up 5.2 %

CPRX opened at $21.66 on Friday. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.16 and a 12-month high of $24.64. The business’s fifty day simple moving average is $22.21 and its 200-day simple moving average is $21.40.

Insider Buying and Selling

In other news, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.